ASCO checkpoint inhibitor battle between Merck and Roche highlights the pitfalls in directly comparing clinical trial results in the era of precision medicine.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
Precision medicine is showing significant signs of success across tumour types.
A type of enzyme called matrix metalloproteinase could be key to the development of “smart” cancer drugs, according to new research.
A team of tiny molecules that work together to make cancer cells less aggressive has been discovered by Australian researchers.
Researchers at the Weizmann Institute of Science, in collaboration with physicians, have conducted a study in mice, in which they used existing drugs in a new combination to help crush potential resistance to treatment.
Clinical trials involving probiotics are failing to report on the safety and harms of these treatments.
Verge Genomics, the drug discovery startup we recently featured in our Top 5 Startups Disrupting Healthcare, has raised $32 million in Series A financing.
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
Even in light of the rising fears of “superbugs” in the world of big pharma, the marginal profits made through the development of antibiotics isn’t enough to justify the research.